InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. More information coming soon.
|03/31/08||Series C||12.9M||Asset Management, Lanfear Capital, OrbiMed Advisors, Sears Capital Management, Sofinnova Ventures, Vivo Ventures||Unknown|